Cited by 16Nanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryAdvanced Drug Delivery Systems

A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes

Open access
Hirata, Yuma, Tashima, Riho, Mitsuhashi, Naoto, Yoneda, Shintaro, Ozono, Mizune, Fukuta, Tatsuya, Majima, Eiji, Kogure, Kentaro·2021·International Journal of Pharmaceutics

Abstract

Modification with antibodies is a useful strategy for the delivery of nanoparticles to target cells. However, the complexity of the required chemical modifications makes them time-consuming and low efficiency, and the orientation of the antibody is challenging to control. To develop a simple, fast, effective, and orientation-controllable technology, we employed staphylococcal protein A, which can bind to the Fc region of antibodies, as a tool for conjugating antibodies to nanoparticles. Specifically, we modified the C-domain dimer of protein A to contain a lysine cluster to create a molecule, DPACK, that would electrostatically bind to anionic liposomes. Using this protein, antibody-modified liposomes can be prepared in 35 min with two steps: (1) interaction of DPACK with liposomes and (2) interaction of an antibody with DPACK-modified liposomes. Binding efficiencies of DPACK with liposomes and IgG with DPACK-modified liposomes were 75% and 72-84%, respectively. Uptake of liposomes modified with anti-epidermal growth factor receptor (EGFR) antibodies via DPACK by EGFR-expressing cancer cells was significantly higher than that of unmodified liposomes, and the liposomes accumulated in tumors and colocalized with EGFR. This simple, fast, effective and orientation-controllable technology for preparing antibody-modified liposomes will be useful for active targeting drug delivery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2021.120966

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • More studies have proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.

    “More studies have also proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.196–198”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [197]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 17 · Cited by 16

Authors
Hirata, Y., Tashima, R., Mitsuhashi, N., Yoneda, S., Ozono, M., Fukuta, T., Majima, E., & Kogure, K.
Affiliations
  • Tokushima University (JP)
  • Wakayama Medical University (JP)
Corresponding author
Kogure, Kentaro
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2021-09
Volume
607
Pages
120966
ISSN
0378-5173 (ISSN-L)
OpenAlex
W3188180310
Cited by
16
References
17
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 2
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • International Journal of Pharmaceutics (acceptedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (acceptedVersion, cc-by-nc-nd)
Funders
University of Tokushima
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
protein A, electrostatic binding, anionic liposomes, antibody conjugation, EGFR targeting, tumor accumulation, tumor cell uptake
MeSH terms
Antibodies, Liposomes, Technology, Drug Delivery Systems, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review